Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + epirubicin + endostatin
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
A combination therapy consisting of docetaxel (a taxane chemotherapy), epirubicin (an anthracycline chemotherapy), and endostatin (recombinant human endostatin/rh-endostatin, an anti-angiogenic agent). This regimen has been studied primarily as neoadjuvant therapy for breast cancer. Clinical trials have shown that adding endostatin to docetaxel and epirubicin chemotherapy produces higher tumor response rates without significantly increasing toxicity compared to docetaxel and epirubicin alone. The combination works through multiple mechanisms: docetaxel disrupts microtubule function, epirubicin intercalates DNA and inhibits topoisomerase II, while endostatin inhibits angiogenesis by targeting endothelial cells and decreasing tumor blood flow and vascular endothelial growth factor (VEGF) expression.
- Other names
- neoadjuvant DEErh-endostatin + docetaxel + epirubicin
02
Targets
ITGA5:ITGB1 (Integrin α5β1)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on docetaxel + epirubicin + endostatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + epirubicin + endostatin.